United Therapeutics Corporation

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-12 EDT			5-day change	1st Jan Change
341.11 ^USD	-1.47%		-2.54%	+55.13%

09-05	Transcript : United Therapeutics Corporation Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 08:00 AM
09-04	United Therapeutics Insider Sold Shares Worth $2,821,050, According to a Recent SEC Filing	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about United Therapeutics Corporation

Transcript : United Therapeutics Corporation Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 08:00 AM	09-05
United Therapeutics Insider Sold Shares Worth $2,821,050, According to a Recent SEC Filing	09-04	MT
Transcript : United Therapeutics Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:50 PM	09-04
Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug	08-28	MT
Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating	08-28	MT
Liquidia Files Legal Challenge Against FDA Decision to Grant 3-Year New Clinical Investigation Exclusivity to Tyvaso DPI	08-22	MT
United Therapeutics Insider Sold Shares Worth $2,318,397, According to a Recent SEC Filing	08-19	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	08-19	MT
Top Midday Decliners	08-19	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	08-19	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	08-19	MT
Sector Update: Health Care	08-19	MT
Liquidia's Hypertension Treatment Gains Tentative FDA Approval	08-19	MT
UBS Adjusts Price Target on United Therapeutics to $365 From $370, Maintains Buy Rating	08-01	MT
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target	08-01	MT
Transcript : United Therapeutics Corporation, Q2 2024 Earnings Call, Jul 31, 2024	07-31
United Therapeutics' Q2 Net Income, Revenue Increase	07-31	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q2 Revenue $714.9M, vs. Street Est of $690.9M	07-31	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	07-31	CI
United Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-31	CI
United Therapeutics Insider Sold Shares Worth $2,409,782, According to a Recent SEC Filing	07-29	MT
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating	07-25	MT
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing	07-17	MT
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating	07-11	MT
Everything's going according to plan	07-11

Chart United Therapeutics Corporation

Duration

Period

More charts

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,168

Sector

Biotechnology & Medical Research

Calendar

2024-10-29 - Q3 2024 Earnings Release (Projected)

More about the company